A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 801–900 of 3,965
Plasma membrane wounding and repair in pulmonary diseases
Cong, X., Hubmayr, R. D., Li, C., & Zhao, X. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00486.2016 · Cited by 50
Pirfenidone for the treatment of idiopathic pulmonary fibrosis
George, P. M., & Wells, A. U. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1295846 · Cited by 51
Chronic Lung Allograft Dysfunction: Evolving Concepts and Therapies
Derhovanessian, A., Wallace, W. D., Lynch, J. P., Belperio, J. A., & WEIGT, S. S. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1618567 · Cited by 50
Qin, W., Liu, B., Yi, M., Li, L., Tang, Y., Wu, B., & Yuan, X. (2018) · Radiation Research · doi:10.1667/rr15017.1 · Cited by 48
Amariei, D. E., Dodia, N., Deepak, J., Hines, S. E., Galvin, J. R., Atamas, S. P., & Todd, N. W. (2019) · Medicina · doi:10.3390/medicina55090580 · Cited by 58
“This loss of normally functioning alveolar capillary units results in a loss of effective surface area for gas exchange, ventilation-perfusion inequality, and a reduced DLCO [12,32,33].”
BackgroundBiondini, D., Cocconcelli, E., Bernardinello, N., Lorenzoni, G., Rigobello, C., Lococo, S., Castelli, G., Baraldo, S., Cosio, M. G., Gregori, D., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01694-z · Cited by 48
Kalluri, M., Luppi, F., Vancheri, A., Vancheri, C., Balestro, E., Varone, F., Moğulkoç, N., Cacopardo, G., Bargagli, E., Renzoni, E. A., et al. (2021) · European Respiratory Review · doi:10.1183/16000617.0026-2021 · Cited by 55
Molecular Signatures of Idiopathic Pulmonary Fibrosis
Konigsberg, I. R., Borie, R., Walts, A. D., Cardwell, J., Rojas, M., Metzger, F., Hauck, S. M., Fingerlin, T. E., Yang, I. V., & Schwartz, D. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0546oc · Cited by 59
Colombi, D., Dinkel, J., Weinheimer, O., Obermayer, B., Buzan, T., Nabers, D., Bauer, C. C., Oltmanns, U., Palmowski, K., Herth, F. J. F., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130653 · Cited by 53
Holtze, C. H., Freiheit, E., Limb, S. L., Stauffer, J. L., Raimundo, K., Pan, W. T., Flaherty, K. R., & Kim, H. J. (2020) · Respiratory Research · doi:10.1186/s12931-020-1315-4 · Cited by 52
Spagnolo, P., Tonelli, R., Samarelli, A. V., Castelli, G., Cocconcelli, E., Petrarulo, S., Cerri, S., Bernardinello, N., Clini, E. M., Saetta, M. P., et al. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2114897 · Cited by 45
Basalova, N. A., Alexandrushkina, N. A., Grigorieva, O., Kulebyakina, M., & Efimenko, A. Y. (2023) · Biomolecules · doi:10.3390/biom13121718 · Cited by 59
Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases
Isshiki, T., Naiel, S., Vierhout, M., Otsubo, K., Ali, P., Tsubouchi, K., Yazdanshenas, P., Kumaran, V. R., Dvorkin‐Gheva, A., Kolb, M. R. J., et al. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108578 · Cited by 53
Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF
Milger, K., Kneidinger, N., Neurohr, C., Reichenberger, F., & Behr, J. (2015) · European Respiratory Journal · doi:10.1183/13993003.00584-2015 · Cited by 50
Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis
Selvaggio, A. S., & Noble, P. W. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-120214-013614 · Cited by 54
Self-citationRoach, K. M., Feghali‐Bostwick, C. A., Wulff, H., Amrani, Y., & Bradding, P. (2015) · Fibrogenesis & Tissue Repair · doi:10.1186/s13069-015-0022-0 · Cited by 55
Luo, F., Le, N., Mills, T., Chen, N., Karmouty‐Quintana, H., Molina, J. G., Davies, J., Philip, K., Volcik, K. A., Liu, H., et al. (2015) · The FASEB Journal · doi:10.1096/fj.15-274845 · Cited by 50
Cardiac manifestations of idiopathic pulmonary fibrosis
Agrawal, A., Verma, I., Shah, V., Agarwal, A., & Sikachi, R. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01023 · Cited by 50
Tzouvelekis, A., Ntolios, P., Karampitsakos, Τ., Tzilas, V., Anevlavis, S., Bouros, E., Steiropoulos, P., Koulouris, N. G., Stratakos, G. K., Froudarakis, Μ. E., et al. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.08.011 · Cited by 50
Martínez, F. J., Afzal, A. S., Smith, J. A., Ford, A. P. D. W., Li, J. J., Li, Y., Kitt, M. M., the Chronic Cough in IPF Study Group, Hussain, I., Sher, M., et al. (2021) · Pulmonary Therapy · doi:10.1007/s41030-021-00162-9 · Cited by 51
Self-citationMolecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis
Velagacherla, V., Mehta, C. H., Nayak, Y., & Nayak, U. Y. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120283 · Cited by 50
Xiao, H., Zhang, G., Liao, X., Li, X., Zhang, J., Lin, H., Chen, Z., & Zhang, X. (2018) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13247 · Cited by 44
Di Martino, E., Provenzani, A., Vitulo, P., & Polidori, P. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020964451 · Cited by 46
King, C. S., Flaherty, K. R., Glassberg, M. K., Lancaster, L., Raghu, G., Swigris, J. J., Argula, R. G., Dudenhofer, R. A., Ettinger, N. A., Feldman, J., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202107-864oc · Cited by 52
Self-citationAspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway
Peng, J., Xiao, X., Li, S., Lyu, X., Gong, H., Tan, S., Dong, L., Sanders, Y. Y., & Zhang, X. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112085 · Cited by 49
Patel, A. S., Miller, E. R., Regis, S. M., Hunninghake, G. M., Price, L. L., Gawlik, M., McKee, A. B., Rieger‐Christ, K., Pinto-Plata, V., Liesching, T. N., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02359-9 · Cited by 48
Personalized medicine in idiopathic pulmonary fibrosis: facts and promises
Spagnolo, P., Tzouvelekis, A., & Maher, T. M. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000187 · Cited by 46
Therapeutic Approach to Adult Fibrotic Lung Diseases
Adegunsoye, A., & Strek, M. E. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.07.027 · Cited by 52
Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions
Ferrara, G., Luppi, F., Birring, S. S., Cerri, S., Caminati, A., Sköld, M. C., & Kreuter, M. (2018) · European Respiratory Review · doi:10.1183/16000617.0076-2017 · Cited by 49
The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?
Ryerson, C. J., & Kolb, M. R. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.02420-2017 · Cited by 51
Kreuter, M., Kögler, H., Trampisch, M., Geier, S., & Richeldi, L. (2019) · Respiratory Research · doi:10.1186/s12931-019-1037-7 · Cited by 49
Fukihara, J., Kondoh, Y., Brown, K. K., Kimura, T., Kataoka, K., Matsuda, T., Yamano, Y., Suzuki, A., Furukawa, T., Sumikawa, H., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02465-2018 · Cited by 49
Gulati, S., & Luckhardt, T. (2020) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s224007 · Cited by 48
Sharawy, M. H., & Serrya, M. S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118454 · Cited by 51
Knipe, R. S., Spinney, J. J., Abe, E. A., Probst, C. K., Franklin, A., Logue, A., Giacona, F., Drummond, M., Griffith, J., Brazee, P. L., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0408oc · Cited by 55
Pirfenidone is a renal protective drug: Mechanisms, signalling pathways, and preclinical evidence
Bai, X., Nie, P., Lou, Y., Zhu, Y., Jiang, S., Li, B., & Luo, P. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174503 · Cited by 59
Majewski, S., Szewczyk, K., Żal, A., Białas, A. J., Miłkowska-Dymanowska, J., & Piotrowski, W. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173864 · Cited by 53
Extracellular Lipids in the Lung and Their Role in Pulmonary Fibrosis
Burgy, O., Loriod, S., Beltramo, G., & Bonniaud, P. (2022) · Cells · doi:10.3390/cells11071209 · Cited by 52
Tissue mechanics coevolves with fibrillar matrisomes in healthy and fibrotic tissues
Dooling, L. J., Saini, K., Anlaş, A. A., & Discher, D. E. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.06.006 · Cited by 46
GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial
Strambu, I. R., Seemayer, C. A., Fagard, L., Ford, P., Aa, T. V. D., de Haas, A., Modgill, V., Santermans, E., Sondag, E., Helmer, E., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01794-2022 · Cited by 53
Novel inhalation therapy in pulmonary fibrosis: principles, applications and prospects
Zheng, M., Zhu, W., Gao, F., Zhuo, Y., Mo, Z., Wu, G., & Feng, C. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02407-6 · Cited by 56
Confronting the Frustrations of Negative Clinical Trials in Acute Respiratory Distress Syndrome
Rubenfeld, G. D. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201409-414mg · Cited by 47
Acute exacerbations in patients with idiopathic pulmonary fibrosis
Kim, D. W. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-86 · Cited by 49
17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice
Yatomi, M., Hisada, T., Ishizuka, T., Koga, Y., Ono, A., Kamide, Y., Seki, K., Aoki‐Saito, H., Tsurumaki, H., Sunaga, N., et al. (2015) · Physiological Reports · doi:10.14814/phy2.12628 · Cited by 50
Ryerson, C. J., Camp, P. G., Eves, N. D., Schaeffer, M. R., Syed, N., Dhillon, S. S., Jensen, D., Maltais, F., O’Donnell, D. E., Raghavan, N., et al. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201604-267oc · Cited by 48
Greater cellular stiffness in fibroblasts from patients with idiopathic pulmonary fibrosis
Jaffar, J., Yang, S.-H., Kim, S. Y., Kim, H., Faiz, A., Chrzanowski, W., & Burgess, J. K. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00030.2018 · Cited by 51
Understanding the patient's experience of care in idiopathic pulmonary fibrosis
Burnett, K., Glaspole, I., & Holland, A. E. (2018) · Respirology · doi:10.1111/resp.13414 · Cited by 44
Self-citationPulmonary Complications of Rheumatoid Arthritis
Farquhar, H. J., Vassallo, R., Edwards, A. L., & Matteson, E. L. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1683995 · Cited by 56
Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases
Liu, F., Bayliss, G. P., & Zhuang, S. (2019) · Clinical Science · doi:10.1042/cs20190249 · Cited by 52
Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0418-6 · Cited by 49
Ayaub, E., Poli, S., Ng, J., Adams, T., Schupp, J., Quesada-Arias, L., Poli, F., Cosme, C., Robertson, M., Martinez-Manzano, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.04.425268 · Cited by 45
Teague, T., Payne, S. R., Kelly, B. T., Dempsey, T. M., McCoy, R. G., Sangaralingham, L. R., & LIMPER, A. H. (2022) · Respiratory Research · doi:10.1186/s12931-022-02001-0 · Cited by 56
Podolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02281-8 · Cited by 52
Self-citationA Novel CD206 Targeting Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice
Ghebremedhin, A., Salam, A. B., Adu-Addai, B., Noonan, S., Stratton, R. J., Ahmed, M. S. U., Khantwal, C. M., Martin, G. R., Lin, H., Andrews, C., et al. (2023) · Cells · doi:10.3390/cells12091254 · Cited by 68
“Pirfenidone and Nintedanib are the only two FDA-approved drugs for lung fibrosis [35,36]; therefore, we tested any synergistic effects of RP-832c peptide with these drugs.”
BackgroundManaging comorbidities in idiopathic pulmonary fibrosis
Ryerson, C. J., & Fulton, B. G. (2015) · International Journal of General Medicine · doi:10.2147/ijgm.s74880 · Cited by 54
The Future of Lung Transplantation
Nathan, S. D. (2015) · CHEST Journal · doi:10.1378/chest.14-1748 · Cited by 49
Self-citationTaguchi, Y., Ebina, M., Hashimoto, S., Ogura, T., Azuma, A., Taniguchi, H., Kondoh, Y., Suga, M., Takahashi, H., Nakata, K., et al. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.06.002 · Cited by 52
“A prespecified pooled analysis including the ASCEND and CAPACITY trials showed that pirfenidone reduced the risk of death at 1 year by 48% [23].”
BackgroundMethodInfluentialAmbulatory and short-burst oxygen for interstitial lung disease
Sharp, C., Adamali, H. I., & Millar, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011716.pub2 · Cited by 66
Mortality and Respiratory Failure After Thoracoscopic Lung Biopsy for Interstitial Lung Disease
Durheim, M. T., Kim, S., Gulack, B. C., Burfeind, W. R., Gaissert, H. A., Kosinski, A. S., & Hartwig, M. G. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.02.013 · Cited by 46
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
Raghu, G. (2017) · European Respiratory Review · doi:10.1183/16000617.0071-2017 · Cited by 45
Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
Tzouvelekis, A., Karampitsakos, Τ., Ntolios, P., Tzilas, V., Bouros, E., Markozannes, E., Malliou, I., Anagnostopoulos, A., GRANITSAS, A. N., Steiropoulos, P., et al. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00213 · Cited by 50
Ramadurai, D., Corder, S., Churney, T., Graney, B. A., Harshman, A., Meadows, S. K., & Swigris, J. J. (2018) · BMJ Open Quality · doi:10.1136/bmjoq-2017-000207 · Cited by 48
Self-citationWilfong, E. M., Lentz, R. J., Guttentag, A. R., Tolle, J., Johnson, J. E., Kropski, J. A., Kendall, P. L., Blackwell, T. S., & Crofford, L. J. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40679 · Cited by 51
Nathan, S. D., LANCASTER, L. H., Albera, C., Glassberg, M. K., Swigris, J. J., Gilberg, F., Kirchgaessler, K.-U., Limb, S. L., Petzinger, U., & Noble, P. W. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000323 · Cited by 48
Self-citationTreating Heart Failure with Preserved Ejection Fraction: Learning from Pulmonary Fibrosis
Graziani, F., Varone, F., Crea, F., & Richeldi, L. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1286 · Cited by 44
Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis
Kreuter, M., Lederer, D. J., Molina‐Molina, M., Noth, I., Valenzuela, C., Frankenstein, L., Weycker, D. A., Atwood, M., Kirchgaessler, K.-U., & Cottin, V. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.04.015 · Cited by 46
Self-citationArish, N., Petukhov, D., & Wallach‐Dayan, S. B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122996 · Cited by 47
Connective Tissue Disease Related Interstitial Lung Disease
Schulte, J. J., & Husain, A. N. (2020) · Surgical pathology clinics · doi:10.1016/j.path.2019.11.005 · Cited by 46
Inhibition of Aurora Kinase B attenuates fibroblast activation and pulmonary fibrosis
Kasam, R. K., Ghandikota, S. K., Soundararajan, D., Reddy, G. B., Huang, S. K., Jegga, A. G., & Madala, S. K. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012131 · Cited by 50
“However, neither of these drugs provide a cure, and both of them are associated with several serious drug-related side effects (King et al, 2014; Richeldi et al, 2014; Hughes et al, 2016).”
BackgroundRyerson, C. J., Corte, T. J., Myers, J. L., Walsh, S. L. F., & Guler, S. A. (2021) · European Respiratory Journal · doi:10.1183/13993003.00276-2021 · Cited by 47
Telomere Shortening and Its Association with Cell Dysfunction in Lung Diseases
Ruíz, A., Flores‐González, J., Buendía-Roldán, I., & Chávez‐Galán, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010425 · Cited by 49
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
Costabel, U., Albera, C., Glassberg, M. K., Lancaster, L. H., Wuyts, W. A., Petzinger, U., Gilberg, F., Kirchgaessler, K.-U., & Noble, P. W. (2019) · Respiratory Research · doi:10.1186/s12931-019-1021-2 · Cited by 43
Self-citationSalvianolic acid B dry powder inhaler for the treatment of idiopathic pulmonary fibrosis
Lü, P., Li, J., Liu, C., Yang, J., Peng, H., Xue, Z., & Liu, Z. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.04.004 · Cited by 54
Diagnosing interstitial lung disease by multidisciplinary discussion: A review
Glenn, L. M., Troy, L. K., & Corte, T. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1017501 · Cited by 50
Pérez, E. R. F., Crooks, J., Lynch, D. A., Humphries, S. M., Koelsch, T. L., Swigris, J. J., Solomon, J. J., Mohning, M. P., Groshong, S. D., & Fier, K. (2023) · Thorax · doi:10.1136/thorax-2022-219795 · Cited by 49
Self-citationWalsh, S. L. F., Backer, J. D., Prosch, H., Langs, G., Calandriello, L., Cottin, V., Brown, K. K., Inoue, Y., Tzilas, V., & Estes, E. A. (2024) · European Respiratory Review · doi:10.1183/16000617.0055-2023 · Cited by 53
Where are we heading to in pharmacological IBD therapy?
Rogler, G. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.005 · Cited by 49
Urushiyama, H., Terasaki, Y., Nagasaka, S., Terasaki, M., Kunugi, S., Nagase, T., Fukuda, Y., & Shimizu, A. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.66 · Cited by 48
Interstitial Lung Disease Evaluation: Detecting Connective Tissue Disease
Fischer, A., Lee, J. S., & Cottin, V. (2015) · Respiration · doi:10.1159/000440665 · Cited by 46
Adegunsoye, A., & Balachandran, J. S. (2015) · Mediators of Inflammation · doi:10.1155/2015/510105 · Cited by 46
Smoking-Related Interstitial Lung Disease
Hagmeyer, L., & Randerath, W. J. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0043 · Cited by 55
Novel drug targets for idiopathic pulmonary fibrosis
Sgalla, G., Cocconcelli, E., Tonelli, R., & Richeldi, L. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1152186 · Cited by 42
Ferrara, G., Carlson, L., Palm, A., Einarsson, J., Olivesten, C., Sköld, M., & Pulmonar, F. T. S. I. (2016) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v3.31090 · Cited by 43
Adegunsoye, A., Hrusch, C. L., Bonham, C. A., Jaffrey, M. R., Blaine, K. M., Sullivan, M., Churpek, M. M., Strek, M. E., Noth, I., & Sperling, A. I. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00516 · Cited by 48
Guidelines for the Medical Treatment of Idiopathic Pulmonary Fibrosis
Xaubet, A., Molina‐Molina, M., Acosta, O., Bollo, E., Castillo, D., Fernández‐Fabrellas, E., Rodríguez-Portal, J. A., Valenzuela, C., & Ancochea, J. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2017.03.001 · Cited by 49
Cell‐specific expression of runt‐related transcription factor 2 contributes to pulmonary fibrosis
Mümmler, C., Burgy, O., Hermann, S., Mutze, K., Günther, A., & Königshoff, M. (2017) · The FASEB Journal · doi:10.1096/fj.201700482r · Cited by 51
Clay, R., Bartholmai, B. J., Zhou, B., Karwoski, R. A., Peikert, T., Osborn, T. G., Rajagopalan, S., Kalra, S., & Zhang, X. (2018) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000334 · Cited by 48
Randomised controlled trials and real-life studies: two answers for one question
Harari, S. A. (2018) · European Respiratory Review · doi:10.1183/16000617.0080-2018 · Cited by 46
Barratt, S. L., Mulholland, S., Al Jbour, K., Steer, H., Gutsche, M., Foley, N., Srivastava, R., Sharp, C., & Adamali, H. I. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01480 · Cited by 43
“Two anti-fibrotic therapies are currently approved for the treatment of IPF based on the results of large scale phase III clinical trials (Noble et al., 2011; King et al., 2014; Richeldi et al., 2014).”
BackgroundMethodResultInfluentialManagement of Fibrosing Interstitial Lung Diseases
Maher, T. M., & Wuyts, W. A. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00992-9 · Cited by 48
Shi, Y., Wong, W. K., Goldin, J. G., Brown, M. S., & Kim, G. H. J. (2019) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2019.101709 · Cited by 54
Transcriptome analysis of IPF fibroblastic foci identifies key pathways involved in fibrogenesis
Guillotin, D., Taylor, A. R., Platé, M., Mercer, P. F., Edwards, L. M., Haggart, R., Miele, G., McAnulty, R. J., Maher, T. M., Hynds, R. E., et al. (2020) · Thorax · doi:10.1136/thoraxjnl-2020-214902 · Cited by 46
“[3, 4] There therefore remains an urgent need to develop novel therapeutic strategies for IPF and other fibrotic conditions.”
BackgroundPractical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis
King, C. S., & Nathan, S. D. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000190 · Cited by 44
Self-citationIdiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra
Rajagopal, K., Bryant, A. J., Sahay, S., Wareing, N. E., Zhou, Y., Pandit, L. M., & Karmouty‐Quintana, H. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15036 · Cited by 51
“Conversely, antifibrotic drug trials (see above) have excluded patients with advanced IPF and/or PH (King et al., 2014; Noble et al., 2011; Richeldi et al., 2014).”
BackgroundMummy, D. G., Bier, E. A., Wang, Z., Korzekwinski, J., Morrison, L. D., Barkauskas, C. E., McAdams, H. P., Tighe, R. M., Driehuys, B., & Mammarappallil, J. G. (2021) · Radiology · doi:10.1148/radiol.2021204149 · Cited by 42
Pergolizzi, J. V., LeQuang, J. A., Varrassi, M., Breve, F., Magnusson, P., & Varrassi, G. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02395-9 · Cited by 47
Xie, Y., Lin, Y., Shi, Y., Su, X., Gan, C., Liu, H., Xue, T., & Ye, T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01753 · Cited by 53
Lederer, D. J., Bradford, W. Z., Fagan, E., Glaspole, I., Glassberg, M. K., Glasscock, K., Kardatzke, D. R., King, T. E., LANCASTER, L. H., Nathan, S. D., et al. (2015) · CHEST Journal · doi:10.1378/chest.14-2817 · Cited by 43
Self-citationChung, J. H., & Lynch, D. A. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.15.15627 · Cited by 49
“Food and Drug Administration for the treatment of IPF after they were shown to slow the decline in pulmonary function over time, which has renewed interest in the accurate diagnosis of IPF [1–3].”
Background“Scar-cinoma”: viewing the fibrotic lung mesenchymal cell in the context of cancer biology
Horowitz, J. C., Osterholzer, J. J., Marazioti, A., & Stathopoulos, G. T. (2016) · European Respiratory Journal · doi:10.1183/13993003.01201-2015 · Cited by 47
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.